Outcomes of Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Anti-PD-1 Therapy, Anti-CTLA-4 Therapy, BRAF Inhibitor, or Conventional Chemotherapy

被引：0
|
作者：
Ahmed, K. A. [1 ]
Abuodeh, Y. A. [1 ]
Hogue, C. [2 ]
Stallworth, D. G. [1 ]
Naghavi, A. O. [1 ]
Kim, S. [1 ]
Sarangkasiri, S. [1 ]
Johnstone, P. A. S. [1 ]
Yu, H. M. [1 ]
Khushalani, N. I. [1 ]
Etame, A. B. [1 ]
Harrison, L. B. [1 ]
Caudell, J. J. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ Louisville, Louisville, KY 40292 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
130
引用
收藏
页码：S58 / S59
页数：2
相关论文
共 50 条
  • [1] Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy
    Ahmed, K. A.
    Abuodeh, Y. A.
    Echevarria, M. I.
    Arrington, J. A.
    Stallworth, D. G.
    Hogue, C.
    Naghavi, A. O.
    Kim, S.
    Kim, Y.
    Patel, B. G.
    Sarangkasiri, S.
    Johnstone, P. A. S.
    Sahebjam, S.
    Khushalani, N. I.
    Forsyth, P. A.
    Harrison, L. B.
    Yu, M.
    Etame, A. B.
    Caudell, J. J.
    ANNALS OF ONCOLOGY, 2016, 27 (12) : 2288 - 2294
  • [2] Stereotactic Radiosurgery and Anti-PD-1+CTLA-4 Therapy, Anti-PD-1 Therapy, Anti-CTLA-4 Therapy, BRAF/MEK Inhibitors, BRAF Inhibitor, or Conventional Chemotherapy for the Management of Melanoma Brain Metastases
    Dohm, A. E.
    Kalagotla, H.
    Jiang, S. X.
    Bhandari, M.
    Mills, M. N.
    Graham, J.
    Khushalani, N. I.
    Forsyth, P.
    Etame, A. B.
    Liu, J. K.
    Tran, N.
    Vogelbaum, M.
    Yu, H. H. M.
    Oliver, D. E.
    Ahmed, K. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E82 - E82
  • [3] Stereotactic radiosurgery and anti-PD-1+CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases
    Dohm, Ammoren E.
    Nakashima, Justyn Y.
    Kalagotla, Hruday
    Jiang, Shirley X.
    Tang, Joseph D.
    Bhandari, Menal
    Kim, Youngchul
    Graham, Jasmine A.
    Khushalani, Nikhil I.
    Forsyth, Peter A.
    Etame, Arnold B.
    Liu, James K.
    Tran, Nam D.
    Vogelbaum, Michael A.
    Wuthrick, Evan J.
    Yu, Hsiang-Hsuan Michael
    Oliver, Daniel E.
    Ahmed, Kamran A.
    EUROPEAN JOURNAL OF CANCER, 2023, 192
  • [4] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [5] Clinical Outcomes of Melanoma Brain Metastases Treated With Stereotactic Radiation and Anti-PD-1 Therapy
    Ahmed, K. A.
    Stallworth, D. G.
    Johnstone, P. A. S.
    Harrison, L. B.
    Etame, A. B.
    Weber, J. S.
    Gibney, G. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S57 - S57
  • [6] Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy
    Ahmed, K. A.
    Stallworth, D. G.
    Kim, Y.
    Johnstone, P. A. S.
    Harrison, L. B.
    Caudell, J. J.
    Yu, H. H. M.
    Etame, A. B.
    Weber, J. S.
    Gibney, G. T.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 434 - 441
  • [7] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [8] CLINICAL OUTCOMES IN THE MANAGEMENT OF MELANOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY AND ANTI-PD-1+CTLA-4
    Tang, Joseph
    Dohm, Ammoren
    Kalagotla, Hruday
    Bhandari, Menal
    Kim, Youngchul
    Graham, Jasmine
    Khushalani, Nikhil
    Forsyth, Peter
    Etame, Arnold
    Liu, James
    Tran, Nam
    Vogelbaum, Michael
    Yu, Michael
    Ahmed, Kamran
    Oliver, Daniel
    NEURO-ONCOLOGY, 2022, 24 : 51 - 51
  • [9] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [10] Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
    da Silva, Ines Pires
    Li, Isabel
    Ugurel, Selma
    Serra-Bellver, Patricio
    Andhale, Avanti
    Burnette, Hannah
    Aya, Francisco
    Conway, Jordan W.
    Braden, Jorja
    Carlino, Matteo S.
    Menzies, Alexander M.
    Weichenthal, Michael
    Mohr, Peter
    Gutzmer, Ralf
    Arance, Ana M.
    Johnson, Douglas B.
    Lorigan, Paul
    Schadendorf, Dirk
    Lo, Serigne N.
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2024, 205
12345